RU-58841 Overview, Dosing & Safety | Peptide Database

RU-58841 (RU58841)

Topical Anti-Androgen | Experimental Hair Loss Treatment

Community Research

Join others researching RU-58841 — share findings, ask questions, and learn from real experiences

RU-58841 is a non-steroidal anti-androgen originally developed by Roussel Uclaf (later Hoechst Marion Roussel) in the 1970s-80s for topical treatment of androgen-dependent conditions including acne and androgenetic alopecia. It works by competitively binding to androgen receptors at the hair follicle, blocking the effects of dihydrotestosterone (DHT) locally without significantly reducing systemic androgen levels. Development was abandoned after Phase II clinical trials, and the compound was never submitted for regulatory approval. Despite this, RU-58841 has developed a substantial following in the hair loss community, where users source it as a raw research chemical and prepare their own topical solutions. Its extremely short systemic half-life means that even if absorbed through the skin, it is rapidly metabolized, limiting systemic anti-androgenic effects. However, the lack of completed clinical trials means its long-term safety profile remains unknown.

RU-58841 functions as a competitive antagonist of the androgen receptor (AR). When applied topically to the scalp, it penetrates the skin and binds directly to androgen receptors in dermal papilla cells of hair follicles, preventing dihydrotestosterone (DHT) and testosterone from activating those receptors. This is fundamentally different from 5-alpha reductase inhibitors like finasteride, which reduce DHT production systemically. RU-58841 does not lower DHT or testosterone levels at all; it simply blocks their action at the receptor level in the tissue where it is applied. The compound has a very high binding affinity for the androgen receptor but an extremely short systemic half-life of roughly one hour due to rapid hydrolysis of its amide bond in the bloodstream. This pharmacokinetic profile is intentional: it confines the anti-androgenic activity to the scalp while minimizing the risk of systemic side effects such as sexual dysfunction or hormonal disruption. Animal studies in hamster flank organ and stumptail macaque models demonstrated significant local anti-androgenic effects, including hair regrowth and inhibition of androgen-dependent sebaceous gland activity, without measurable systemic anti-androgenic effects at therapeutic topical doses.

Molecular Data

Research Indications

Primary intended use. Blocks DHT at the follicular androgen receptor to prevent miniaturization. Animal models showed significant efficacy, and anecdotal reports from the hair loss community are broadly positive, but no completed Phase III trials exist.

Targeted topical application allows concentration on the most androgen-sensitive areas of the scalp. Users typically apply directly to areas of thinning or recession.

Often used alongside finasteride and/or minoxidil as part of a multi-target approach. The distinct mechanism of action (receptor blockade vs. DHT reduction vs. vasodilation) provides theoretical rationale for combination use.

Dosing Protocols

RU-58841 is used exclusively as a topical solution applied to the scalp. It is not available as a commercial pharmaceutical product. Users typically purchase raw powder and dissolve it in a vehicle such as ethanol, propylene glycol, or a combination of the two. The standard concentration used in the community is 50mg/mL (5%), applied once daily. The solution is applied with a dropper or spray to affected areas of the scalp and allowed to dry. Consistency of daily application is important for maintaining receptor blockade at the follicle.

Hair loss treatment (standard community protocol)

50mg (1mL of 50mg/mL solution)

Once daily

Topical application to affected scalp areas

Hair loss treatment (conservative)

25mg (1mL of 25mg/mL solution)

Interactions

What to Expect

Side Effects & Safety

Common Side Effects

Scalp irritation, dryness, or itching at the application site (often related to the vehicle/solvent rather than RU-58841 itself)

Contact dermatitis in sensitive individuals

Scalp flaking or peeling

Stop Signs - Discontinue if:

Severe or persistent scalp irritation, blistering, or open sores

Signs of systemic anti-androgenic effects (sexual dysfunction, breast tenderness, significant fatigue)

Allergic reaction (facial swelling, difficulty breathing, widespread rash)

Any unexplained systemic symptoms that correlate with use

Contraindications

Women who are pregnant or may become pregnant (anti-androgens can cause feminization of a male fetus)

Women who are breastfeeding

Known hypersensitivity to RU-58841 or related non-steroidal anti-androgens

Active scalp infections, open wounds, or severely compromised skin barrier on the scalp

Individuals taking systemic anti-androgens (risk of additive anti-androgenic effects)

Quality Checklist

Good Signs

Purchased from a reputable research chemical supplier with third-party testing

Certificate of analysis (COA) provided showing purity of 99% or higher

Powder is fine, white to off-white, and free of clumps or discoloration

Stored properly (refrigerated, protected from light and moisture)

Solution prepared with pharmaceutical-grade solvents at accurate concentrations

Warning Signs

Supplier does not provide a certificate of analysis or third-party testing

Powder has unusual color, odor, or texture

Purchased from a source with limited or no reputation in the community

Pre-mixed solutions without clear labeling of concentration or ingredients

Bad Signs

No testing documentation of any kind available

Purchased from unknown or unverified sources

Powder that is yellow, brown, or has a strong chemical odor

Solution that appears cloudy, contains particulates, or has separated

Product sold with therapeutic claims (illegal for an unapproved compound)

Frequently Asked Questions

Is RU-58841 absorbed systemically enough to cause sexual side effects?

RU-58841's extremely short systemic half-life (~1 hour) due to rapid hydrolysis means only minimal amounts reach systemic circulation even if absorbed through the skin. The topical mechanism limits anti-androgenic effects to the scalp, making it fundamentally safer than systemic 5-alpha reductase inhibitors for sexual function.

Does RU-58841 work better than finasteride for male pattern baldness?

RU-58841 operates through a different mechanism (local AR blockade vs. DHT suppression), so they're complementary rather than competitive. Stacking both targets hair loss from two angles—finasteride reduces DHT systemically while RU-58841 blocks it locally at the follicle receptor, which many users report works better than either alone.

How long before RU-58841 stops hair loss?

Users typically report stabilization of hair loss (reduced shedding) within 2-3 months of daily application, with early signs of regrowth appearing around 4-6 months. Results vary significantly—some see dense regrowth while others only achieve stabilization, likely depending on how many follicles are dormant vs. permanently lost.

What happens if I stop using RU-58841?

Since RU-58841 only blocks DHT at the receptor level without reducing systemic DHT, discontinuation allows hair loss to resume as DHT signaling returns to the follicle. Continuous daily application is required to maintain any benefit—unlike finasteride which provides some carryover effect after stopping.

References

Characterized RU-58841 as a potent non-steroidal anti-androgen with high affinity for the androgen receptor. Demonstrated strong topical anti-androgenic activity with minimal systemic effects in animal models, establishing its pharmacological profile as a locally active anti-androgen suitable for dermatological applications.

Evaluated RU-58841 and other anti-androgens in stumptail macaques, a primate model for androgenetic alopecia. Topical RU-58841 application promoted hair regrowth and increased hair follicle size without systemic anti-androgenic side effects, supporting the concept of localized androgen receptor blockade for treating hair loss.

Demonstrated that topical application of RU-58841 to the androgen-sensitive hamster flank organ produced significant local anti-androgenic effects, including reduction of sebaceous gland size, without affecting contralateral untreated organs or systemic androgen markers. Confirmed the compound's ability to act locally without systemic absorption.

Reviewed the landscape of topical anti-androgens under development for androgenetic alopecia, with RU-58841 highlighted as one of the most promising candidates. Discussed the rationale for topical anti-androgen therapy, the pharmacokinetics favoring local over systemic activity, and the unmet clinical need for agents that could block androgen action at the follicle without hormonal side effects.

Related Peptides

Highly complementary mechanisms. Finasteride reduces systemic DHT production via 5-alpha reductase inhibition, while RU-58841 blocks remaining DHT (and testosterone) from activating androgen receptors at the follicle. This dual approach addresses hair loss from two different angles and is one of the most common combination strategies in the hair loss community.

Minoxidil promotes hair growth through vasodilation and potassium channel opening, a mechanism entirely independent of androgen signaling. Combining with RU-58841 addresses both the androgen-driven cause of miniaturization and the blood supply to follicles. Many users apply both topicals in the same daily routine, though they should be applied separately to ensure proper absorption of each.

Similar rationale to the finasteride combination. Dutasteride inhibits both Type I and Type II 5-alpha reductase isoforms, providing more aggressive DHT suppression than finasteride. Adding RU-58841 blocks any remaining androgens at the receptor. This is considered an aggressive combination and is typically reserved for advanced hair loss.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.